- Home
- HSPO vs CLRB Comparison
HSPO vs CLRB Comparison
Compare HSPO & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- CLRB
- Stock Information
- Founded
- HSPO 2014
- CLRB 2002
- Country
- HSPO United States
- CLRB United States
- Employees
- HSPO N/A
- CLRB N/A
- Industry
- HSPO Blank Checks
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- CLRB Health Care
- Exchange
- HSPO Nasdaq
- CLRB Nasdaq
- Market Cap
- HSPO 88.3M
- CLRB 76.0M
- IPO Year
- HSPO 2022
- CLRB N/A
- Fundamental
- Price
- HSPO $11.28
- CLRB $1.86
- Analyst Decision
- HSPO
- CLRB Strong Buy
- Analyst Count
- HSPO 0
- CLRB 2
- Target Price
- HSPO N/A
- CLRB $21.00
- AVG Volume (30 Days)
- HSPO 6.2K
- CLRB 289.0K
- Earning Date
- HSPO 01-01-0001
- CLRB 11-18-2024
- Dividend Yield
- HSPO N/A
- CLRB N/A
- EPS Growth
- HSPO N/A
- CLRB N/A
- EPS
- HSPO 0.28
- CLRB N/A
- Revenue
- HSPO N/A
- CLRB N/A
- Revenue This Year
- HSPO N/A
- CLRB N/A
- Revenue Next Year
- HSPO N/A
- CLRB N/A
- P/E Ratio
- HSPO $40.04
- CLRB N/A
- Revenue Growth
- HSPO N/A
- CLRB N/A
- 52 Week Low
- HSPO $10.63
- CLRB $1.82
- 52 Week High
- HSPO $11.30
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- HSPO 63.55
- CLRB 30.70
- Support Level
- HSPO $11.17
- CLRB $1.97
- Resistance Level
- HSPO $11.30
- CLRB $2.18
- Average True Range (ATR)
- HSPO 0.00
- CLRB 0.10
- MACD
- HSPO 0.00
- CLRB -0.01
- Stochastic Oscillator
- HSPO 60.00
- CLRB 8.11
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.